When a therapy enters the Australian funding process, the evidence behind it is typically compelling. To even consider listening from MSAC {for diagnostics and medical devices} or PBAC {for medicines} most innovations come with strong clinical data, meaningful endpoints, and clear potential for improving patient lives. Yet many still find themselves waiting months, or even years, for movement.
Progress often stalls because the issue doesn’t yet sit high enough on the political agenda.
Australia’s health system is deliberately cautious. Committees are designed to evaluate methodically. Departments must manage competing pressures within tight budgets. Without signals that an issue matters beyond the paperwork, progress can slow dramatically.
Three dynamics consistently shape whether a therapy gains traction.
When decision-makers do not hear about a therapy outside the formal submission process, it remains one item among many. What shifts this is visibility from the right voices.
Collectively, these interactions show that an issue is active, they give policymakers confidence that the therapy has relevance and solves a problem that matters to Australian voters right now.
When the right people see and hear about the therapy, the evidence gains clearer relevance in the political environment.
Departments evaluate data. Politicians respond to impact. When a therapy’s value is explained only through numbers, it risks being deprioritised. After all, every therapy has strong evidence that is addresses a clinical issue, but by definition, you can’t fund every innovation.
But when a minister hears directly from a clinician who cannot offer a better solution, or from a parent managing the daily consequences of an unmanaged condition, the issue becomes tangible. Emotional. Real.
Human stories help decision-makers understand what delay means for real people: lost productivity, unmet need, reduced independence, or ongoing strain on hospital capacity.
Stories sharpen the stakes in ways spreadsheets cannot.
Government bodies operate independently, but independence does not mean isolation. Policymakers take notice when colleagues, constituents, and respected organisations consistently raise an issue.
It prompts decision-makers to engage more closely with the matter and understand its rising importance.
Sustained visibility signals to ministers and departments that the status quo is no longer acceptable. The result can be meaningful:
Therapies that gain this kind of momentum are rarely those that sit silently in the system waiting to be rediscovered.
For companies entering the Australian market, it’s easy to assume clinical value will speak for itself. But in a system with limited bandwidth, contained budgets, and many competing priorities, value must also be seen, heard, and felt.
The innovations that move fastest are those with:
Success relies on both evidence and engagement. When they work together, a therapy becomes much harder to ignore, and far more likely to progress.
Evidence earns attention. Visibility earns action.
For medical innovators, this distinction is often what separates therapies that stall from those that advance.
If building this kind of momentum is a priority for your organisation, London Agency’s team works with companies to ensure their value is understood, both scientifically and politically.
